Drug Discovery@nature.com 14 October 2011

Advertisement Discover Relevant Variance Don't risk valuable time and resources using tools that fail to generate biologically relevant data for pharmacogenetic research. Isolate the data you need, at the cost you want, with Sequenom's iPLEX® ADME PGx panel. Change the course of your research today with the iPLEX ADME PGX Find out more here TABLE OF CONTENTS 14 October 2011 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement A personalized experience in clinical trial publishing Network with Pharma Solutions on Linked In. Our group connects key decision makers in clinical trial publishing, including lead investigators, pharmaceutical companies, and medical communication agencies. Join in discussions and hot topics shaping the industry.   News Top Trial watch: IL-13 antibody improves lung function in asthma doi:10.1038/nrd3562 Lebrikizumab, a humanized monoclonal antibody that targets interleukin-13, has demonstrated improved lung function in adults with uncontrolled asthma in a Phase II clinical trial. Full Text Trial watch: First-in-human studies with cardiac myosin activators doi:10.1038/nrd3563 Omecamtiv mecarbil has shown encouraging results in a Phase I trial and a small Phase II trial as the first in a new potential class of drugs to treat heart failure by targeting myosin. Full Text Market watch: Upcoming market catalysts in Q4 2011 doi:10.1038/nrd3564 Highlights include impending approval decisions on dapagliflozin and on ruxolitinib; top-line results from a Phase III trial of alemtuzumab in relapsing–remitting multiple sclerosis are also expected. Full Text France toughens conflict rules doi:10.1038/478169a Law demands greater transparency for health experts. Full Text Analysis Top Opening the brain doi:10.1038/scibx.2011.1080 Adenios Inc. has licensed a new strategy to deliver large-molecule therapeutics into the central nervous system - agonizing adenosine receptors in the brain's vasculature - and is developing compounds as adjunct therapies for neurological indications. Full Text Ezogabine (retigabine) doi:10.1038/nrd3561 Ezogabine, a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine. Full Text Antibacterial R&D incentives doi:10.1038/nrd3560 This article outlines the objectives of incentives for antibacterial R&D and compares the ability of various incentive policies to address the long-term challenge of antibacterial resistance. Full Text Research Highlights Top Antivirals: New clues for flu vaccine design doi:10.1038/nrd3567 Human monoclonal antibodies exhibiting broad neutralizing activity against type A influenza viruses have been identified. Full Text Synthetic biology: Licensing bacteria to kill doi:10.1038/nrmicro2660 Reports on the design and testing of an engineered Escherichia coli strain that specifically targets Pseudomonas aeruginosa. Full Text Immunotherapy: Leukadherins get a grip on inflammation doi:10.1038/nri3079 New drugs promoting integrin activation prevent inflammatory cells from being recruited to inflamed tissues. Full Text Research & Reviews Top The influence of the 'organizational factor' on compound quality in drug discovery doi:10.1038/nrd3552 The results of an in-depth comparison of patented compounds from different companies acting on the same targets indicates the continued production of compounds with suboptimal physiochemical profiles. Full Text Development of subtype-selective oestrogen receptor-based therapeutics doi:10.1038/nrd3551 This article outlines the roles of oestrogen receptor [alpha] and oestrogen receptor [beta] in various animal disease models, and details how agonists that selectively target either receptor subtype might provide a more efficacious therapy than targeting both for certain diseases. Full Text The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension doi:10.1038/nm.2497 This article describes how thiazide diuretics could be used to prevent hypertension mediated by activation of the renal sodium chloride cotransporter that is associated with the use of calcineurin inhibitor immunosuppressants. Full Text Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia doi:10.1038/nature10509 In this study, a novel small molecule inhibitor of the BET family has been shown to displace BET proteins from chromatin to induce early cell cycle arrest and apoptosis in MLL-fusion leukaemic cell lines and to provide survival benefit in two mouse models of leukaemia. Full Text Drug Discovery JOBS of the week Pharmaceutical Primary Care Sales Representative Musculoskeletal (50431946) Lilly USA, LLC Tucson, US Research Associate in Bioinformatics The University of Hong Kong Hong Kong, HK PhD position: Automated Analysis of Dynamic Properties in Biological Systems from Image Data International Leibniz Research School for Microbial and Biomolecular Interactions Jena, DE Postdoctoral Position - Gene Expression Laboratory The Salk Institute for Biological Studies La Jolla, US Staff Scientist The Institute of Cancer Research (ICR) London, GB More Science jobs from Drug Discovery EVENT Quality Risk Management in Clinical Drug Development Conference 2011 27.-28.10.11 Berlin, Germany More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.